Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Beat Estimates

Halozyme Therapeutics (HALO) came out with quarterly earnings of $0.91 per share, beating the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.74 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 16.67%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $0.69 per share when it actually produced earnings of $0.79, delivering a surprise of 14.49%. Over the last f ...